Dr. Reddy's Laboratories

Sees M&A scope in slowdown

Daily News Analysis (Free subscription) | 05/09/2008

Dr Reddy's Laboratories, one of the leading players in the country's pharma sector, is now planning to make use of such opportunities for inorganic growth.

Reddy's, US firm in marketing deal

Daily News Analysis (Free subscription) | 05/09/2008

Dr Reddy's Laboratories Ltd has entered into a licensing and distribution agreement with Cosmederm Technologies.

• CORRECTING and REPLACING Cosmederm Technologies Announces Partnership with Dr. Reddy´s for Indian .. - EuroInvestor.co.uk
• Cosmederm Signs Licensing and Distribution Agreement With Dr Reddy's - Red Orbit
• See the 8 articles on the same subject

Dr Reddy’s to market US skincare products

Thaindian News (Free subscription) | 04/09/2008

New Delhi, Sep 4 (IANS) Dr.Reddy’s Laboratories Thursday announced a licensing and distribution agreement with Cosmederm Technologies for distribution of the latter’s skincare products in India.The US-based company will partner with Dr Reddy’s for two products, namely Refinity peel kits (Glycolic acid 70 percent) and Cosmederm peel kits (Glycolic acid 50 percent), a company statement [...]

• Cosmederm Technologies Announces Partnership with Dr. Reddy's for Indian Distribution of Proprietary Skin Care Products - The Earth Times Online Newspaper
• Cosmederm Technologies Announces Partnership with Dr. Reddy's for Indian Distribution of Proprietary Skin Care Products - Business Wire

Price fall hurting Betapharm: Dr Reddy's

Daily News Analysis (Free subscription) | 30/08/2008

Dr Reddy's Laboratories Ltd (DRL) is facing significant pressure on its business in Germany as regulations and growing competition drive down prices, its chief executive said.

Reddy's will hive off skincare biz

Daily News Analysis (Free subscription) | 20/08/2008

As part of plans to up its focus on specialty pharma, the NYSE- listed Dr Reddy's Laboratories is all set to hive off its dermatology business into a new entity called Promius Pharma.

Pricing, cost may hit Dr Reddy's AOK bid

Daily News Analysis (Free subscription) | 15/08/2008

Increasing pricing pressures and high fixed-cost base are likely to affect the prospects of Dr Reddy's Laboratories in tapping a massive opportunity being provided by AOK.

Teva and Dr. Reddy's Settle Coreg® Suit

Patent Docs (Free subscription) | 02/08/2008

By Sherri Oslick -- Earlier this week the litigation between Teva Pharmaceutical Industries Ltd. and Dr. Reddy's Laboratories Inc. over generic Coreg® was dismissed without costs and without prejudice based on a settlement between the parties. As we reported previously, the suit was originally filed in the District Court of New Jersey on June 21, 2007 against Dr. Reddy's for infringement of U.S. Patent...

Biosimilars, Indian Generic Companies and the Drug Regulators

SPICY IP (Free subscription) | 31/07/2008

The Business Standard reports that " Dr Reddy’s Laboratories, the country’s third-biggest drugmaker, will form a joint venture with one of the world’s biggest biotech companies to make biosimilars or generic versions of patented biotech drugs to take on Ranbaxy Laboratories, Reliance Life Sciences, among other Indian companies. Several drugs are expected to come off patent in this segment in the next...

Potential Therapeutic Compounds Not Obvious Absent A Predictable Solution

Patent Baristas (Free subscription) | 25/07/2008

The United States Court of Appeals for the Federal Circuit found in favor of Eisai in Aciphex patent infringement suit against Teva Pharmaceuticals and Dr. Reddy’s Laboratories . Eisai v. Dr. Reddy’s and Teva (07-1397/98) After Eisai filed infringement actions contesting Teva Pharmaceuticals and Dr. Reddy’s Laboratories’ submission of abbreviated new drug applications (ANDAs) to the [...]

Reddy's loses plea in US on ulcer drug

Daily News Analysis (Free subscription) | 23/07/2008

Dr Reddy's Laboratories may have lost a $100 million profit opportunity with the US Court of Appeals for the Federal Circuit on Monday

Eisai Co. v. Dr. Reddy's Laboratories, Inc. (Fed. Cir. 2008)

Patent Docs (Free subscription) | 22/07/2008

By Kevin E. Noonan -- Sanity may be returning to the Federal Circuit's treatment of two issues, obviousness and inequitable conduct. In Eisai Co. v. Dr. Reddy's Laboratories, Inc., the Court (in an opinion by Judge Rader joined by Judges Linn and Proust) affirmed the District Court's determination that the patent-in-suit, U.S. Patent No. 5,045,552 was not obvious and was not obtained through inequitable...

U.S. Federal Circuit Court of Appeals Fully Upholds Eisai's Favorable Ruling in Aciphex(R) Patent Infringement Lawsuit Against Teva Pharmaceuticals and Dr. Reddy's Laboratories

Red Orbit (Free subscription) | 22/07/2008

TOKYO and WOODCLIFF LAKE, N.J., July 21 /PRNewswire/ -- With respect to Eisai's patent infringement lawsuit against Teva Pharmaceuticals and Dr. Reddy's Laboratories concerning Aciphex(R) (generic name: rabeprazole sodium tablets, Product Name in Japan: Pariet(R)), Eisai Co., Ltd. and its U.S.

• U.S. Federal Circuit Court of Appeals Fully Upholds Eisai's Favorable Ruling in Aciphex(R) Patent Infringement Lawsuit Against Teva Pharmaceuticals and Dr. Reddy's Laboratories - PR News Wire

Citigroup, ICICI to exit Dr Reddy's unit

The Telegraph India (Free subscription) | 21/07/2008

Mumbai, July 21: Dr Reddy's Laboratories (DRL) will buy out the stakes of Citigroup Venture Capital and ICICI Venture Funds Management Company in research and development firm Perlecan Pharma.

Dr. Reddy's profit falls 28% as expenses rise

Market Watch (Free subscription) | 21/07/2008

LONDON (MarketWatch) -- Indian generic drugmaker Dr. Reddy's Laboratories said Monday that net profit in its fiscal first quarter ending June 30 fell 28% to $31 million, or 19 cents a share, from $43 million, or 25 cents a share a year earlier. Revenue for the period rose 25% to $350 million under U.S. generally accepted accounting principles. The group said revenue growth was driven by its key markets...

Dr. Reddy's Q1 FY09 Revenue at Rs. 15,038 Million; EBITDA at Rs. 2,710 Million, PAT at Rs. 1,346 Million

Business Wire (Free subscription) | 21/07/2008

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (NYSE:RDY) today announced its unaudited financial results for the quarter ended June 30,